• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Combination therapy using conformation-specific KIT inhibitors associated with clinical benefit in patients with advanced gastrointestinal stromal tumors

bySuchita Nety
July 20, 2021
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The use of a type I KIT inhibitor, such as PLX9486, in combination with a type II inhibitor, such as sunitinib, was associated with clinical benefit and well tolerated in drug-naïve patients with advanced refractory gastrointestinal stromal tumors.

2. This combination therapy achieved better global disease control and allowed treatment to target a broader spectrum of conformationally distinct oncogenic-resistant mutations.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Gastrointestinal stromal tumors (GISTs) and its mutant subtypes, including KIT-mutant forms, are frequently caused by the activation of tyrosine kinase mutations. As such, treatment using kinase inhibitors often provide effective short-term therapy before relapse occurs due to the proliferation of heterogeneous subclones with resistant mutations. In recent years, conformation-specific KIT inhibitors have been used to target advanced GISTs. However, their mechanism of action in targeting these cancer subtypes as well as the clinical benefits of various monotherapy dosing and combination therapies are not well understood. This two-part phase 1b/2a nonrandomized clinical trial sought to evaluate whether PLX9486, a type I KIT inhibitor, could be combined with a type II KIT inhibitor, such as sunitinib, to target a broad spectrum of oncogenic mutations and achieve global disease control. The main outcomes and measures of the analysis were pharmacokinetics, safety, and tumor responses. In addition, clinical efficacy end points assessed via progression-free survival and clinical benefit rate were supplemented with longitudinal monitoring of KIT mutations in circulating tumor DNA. From 39 PLX9486-naïve patients with refractory GIST, PLX9486 (a selective type I KIT inhibitor targeting activation-loop mutations) use together with sunitinib (a type II inhibitor targeting adenosine triphosphate-binding pocket mutations) achieved the highest median progression-free survival of 12.1 months and the highest clinical benefit rate of 80% among various uses and dosages of the agents. These results suggested that the use of a type I KIT inhibitor, such as PLX9486, in combination with a type II inhibitor, such as sunitinib, was well tolerated in drug-naïve patients with advanced refractory GIST. Furthermore, this combination therapy achieved better global disease control and allowed treatment to target a broader spectrum of conformationally distinct oncogenic-resistant mutations. A limitation of this study was the small sample size and heterogeneity present throughout disease progression that can produce residual confounding effects when attempting to study the outcomes of specific combinations of drug-resistant subclones. Long-term randomized clinical trials comparing PLX9486 monotherapy to combination therapy with sunitinib are needed to evaluate specific inhibitory mechanisms of drug-resistance and overall clinical outcomes.

Click to read the study in JAMA

Relevant Reading: A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

In-Depth [randomized controlled trial]: This two-part phase 1b/2a nonrandomized clinical trial tested a highly selective type I inhibitor of KIT, PLX9486, by enrolling 39 PLX9486-naïve patients (median age, 57 years [range, 39-79 years]; 22 men [56.4%]; 35 [89.7%] with refractory GIST). The initial part of the trial (dose escalation) evaluated PLX9486 monotherapy in patients with solid tumors while the second part (extension) evaluated PLX9486-sunitinib combination in patients with GIST. Data was collected from March 2015 to February 2019 with analysis completed by July 2020. In part 1, patients received 250, 350, 500, and 1000mg of PLX9486 monotherapy. In part 2, the recommended dose of PLX9486 was 500 and 1000mg combined with 25 or 37.5mg daily of sunitinib continuously administered in 28-day dosing cycles until disease progression, treatment discontinuation, or withdrawal. Patients with GIST who received PLX9486 at a dose of 500mg or less had a median progression-free survival of 1.74 (95%CI, 1.54-1.84) months along with a clinical benefit rate of 14% (95%CI, 0%-58%). Patients who received PLX9486 at the recommended phase 2 dose had a median progression-free survival of 5.75 (95%CI, 0.99-11.0) months along with a clinical benefit rate of 50% (95%CI, 21%-79%). Lastly, PLX9486 use together with sunitinib had a median progression-free survival of 12.1 (1.34-NA) months and a clinical benefit rate of 80% (95%CI, 52%-96%).

RELATED REPORTS

2 Minute Medicine Rewind, May 16

Lenvatinib plus pembrolizumab show similar health-related quality-of-life outcomes in patients with advanced renal cell carcinoma compared to sunitinib

2 Minute Medicine Rewind May 2, 2022

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: gastrointestinal stromal tumorsgistkinaseKIToncologyPLX9486sunitinibtargeted therapy
Previous Post

Coronary artery calcium scoring associated with significant improvements in atherosclerotic cardiovascular disease reclassification when guiding statin therapy

Next Post

Inequities in aortic stenosis and aortic valve replacement between black/African American, white, and Hispanic patients

RelatedReports

Image-guided percutaneous drainage of pericardial effusions is safe and effective
Weekly Rewinds

2 Minute Medicine Rewind, May 16

May 16, 2022
Increased number of daily steps linked with decreased mortality in older women

Lenvatinib plus pembrolizumab show similar health-related quality-of-life outcomes in patients with advanced renal cell carcinoma compared to sunitinib

May 2, 2022
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Weekly Rewinds

2 Minute Medicine Rewind May 2, 2022

May 2, 2022
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Oncology

Comparison of mastectomy and breast reconstruction versus conservative surgery with radiation

April 26, 2022
Next Post
Survival greater in cervical cancer patients undergoing abdominal hysterectomy compared to minimally invasive techniques: the LACC trial

Inequities in aortic stenosis and aortic valve replacement between black/African American, white, and Hispanic patients

Mental health parity law associated with financial protection for children

Laughter yoga may attenuate cortisol release in response to stress

Compliance-linked incentives increase infant immunizations rates in rural India

Mixed vaccination with ChAdOx1-S followed by BNT162b2 induces a robust humoral immune response

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events
  • Early onset Lewy Body Dementia is more clinically distinct from Alzheimer Dementia than late onset Lewy Body Dementia
  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.